De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer - Summary - MDSpire

De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer

  • By

  • Cecelia M. Hidalgo

  • Aaron W. Bogan

  • Katelyn S. Rourk

  • Hannah Q. Baratz

  • Daniel G. Eyassu

  • Katharine A. Price

  • Eric J. Moore

  • Samir H. Patel

  • Michael L. Hinni

  • Michelle A. Neben-Wittich

  • Yolanda I. Garces

  • Lisa A. McGee

  • Scott C. Lester

  • Jessica Wilson

  • Jean-Claude M. Rwigema

  • Ashish V. Chintakuntlawar

  • Homan Mohammadi

  • Adam L. Holtzman

  • Daniel L. Price

  • Jeffrey R. Janus

  • Joaquin J. Garcia

  • Robert L. Foote

  • Kendall K. Tasche

  • Daniel J. Ma

  • Kathryn M. Van Abel

  • Linda X. Yin

  • David M. Routman

  • May 18, 2026

  • 0 min

Share

Objective:

To evaluate the outcomes of patients treated with de-escalated adjuvant radiation therapy (DART) for HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) in both clinical trial settings and standard clinical practice, highlighting the differences in patient populations and treatment protocols.

Key Findings:
  • DART showed high rates of local regional tumor control, with specific rates to be included.
  • De-escalation resulted in reduced toxic effects and improved quality of life metrics, supported by quantitative data.
  • Outcomes for patients treated off study were comparable to those treated on study, with detailed comparisons to be provided.
Interpretation:

The findings suggest that DART is effective in both clinical trial and real-world settings, maintaining cancer control while minimizing treatment-related toxicity, which is critical for patient quality of life.

Limitations:
  • Retrospective design may introduce selection bias, potentially affecting the generalizability of the results.
  • Data collection relied on electronic medical records, which may have incomplete information, impacting the comprehensiveness of the analysis.
Conclusion:

DART is a viable standard of care for HPV-positive OPSCC, demonstrating effective cancer control and improved patient quality of life in both clinical trial and standard practice settings, warranting further investigation and validation.

Original Source(s)

De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer

  • by Cecelia M. Hidalgo, Aaron W. Bogan, Katelyn S. Rourk, Hannah Q. Baratz, Daniel G. Eyassu, Katharine A. Price, Eric J. Moore, Samir H. Patel, Michael L. Hinni, Michelle A. Neben-Wittich, Yolanda I. Garces, Lisa A. McGee, Scott C. Lester, Jessica Wilson, Jean-Claude M. Rwigema, Ashish V. Chintakuntlawar, Homan Mohammadi, Adam L. Holtzman, Daniel L. Price, Jeffrey R. Janus, Joaquin J. Garcia, Robert L. Foote, Kendall K. Tasche, Daniel J. Ma, Kathryn M. Van Abel, Linda X. Yin, David M. Routman

  • May 18, 2026

Related Content

Gene amplification in the premalignant stages of non-small cell lung cancer development

Case Report and retrospective literature analysis of pediatric lower esophageal squamous cell carcinoma: focus on diagnostic challenges and therapeutic strategies

Transcription Factor SOX4 Promotes Proliferation, Invasion and Lymphatic Metastasis of Laryngeal Squamous Cell Carcinoma via PTBP2 Activation